The FDA has granted approval to Pfizer's Abrysvo, the first vaccine designed to protect newborns from respiratory syncytial virus (RSV).

The US FDA has granted approval to Pfizer for a vaccine named Abrysvo that safeguards newborns from respiratory syncytial virus (RSV). Given to mothers during late pregnancy, the vaccine provides protection to infants for their first six months of life. RSV is a common cause of infant illness and hospitalization, particularly during winter months. In a trial involving over 7,000 pregnant individuals and their infants, the vaccine demonstrated effectiveness in reducing hospitalizations and doctor visits for RSV-related issues. While not providing long-term protection, the vaccine offers significant potential benefits in curbing RSV's impact on infants.